Flywire Analysts Slash Their Forecasts After Q3 Results

Flywire Corporation (NASDAQ: FLYW) posted a profit for its third quarter on Tuesday.

Flywire Corporation (NASDAQ:FLYW) posted a profit for its third quarter on Tuesday.

Flywire posted earnings of 8 cents per share for the third quarter, versus a year-ago loss of 4 cents per share. The company’s revenue came in at $123.3 million versus estimates of $122.07 million.

Flywire said it sees FY23 revenue of $394.1 million to $399.3 million, versus estimates of $385.17 million.

Flywire also said it has acquired StudyLink, an innovative provider of international student admissions, application and agent management software serving universities throughout Australia.

Flywire shares fell 26.9% to trade at $20.23 on Wednesday.

These analysts made changes to their price targets on Flywire following earnings announcement.

  • Raymond James slashed the price target on Flywire from $44 to $35. Raymond James analyst John Davis maintained a Strong Buy rating.
  • Goldman Sachs cut the price target on Flywire from $37 to $33. Goldman Sachs analyst Will Nance maintained a Buy rating.
  • Wells Fargo lowered the price target on Flywire from $35 to $33. Wells Fargo analyst Jeff Cantwell maintained an Overweight rating.
  • Truist Securities cut the price target on Flywire from $40 to $33. Truist Securities analyst Andrew Jeffrey maintained a Buy rating.

Now Read This: Disney Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Total
0
Shares
Related Posts
Read More

Incyte Announced Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental Vitiligo; Said Patients Treated With Povorcitinib Experienced Improvements In Total Body And Facial Repigmentation

Incyte (Nasdaq: INCY) today announced new data from a Phase 2b clinical trial evaluating the safety and efficacy of povorcitinib (INCB54707), an investigational oral JAK1 inhibitor, in adult patients with extensive nonsegmental vitiligo.

INCY